Jian Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jian Zhao has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Desiree R. Azizoddin
Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
3 shared publications - Hailey W. Bulls
Challenges in Managing and Preventing Pain (CHAMPP) Clinical Research Center, Div of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA
3 shared publications Kristin L. Schreiber
Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Boston, MA
3 shared publicationsSusan Sereika
2 shared publicationsAli John Zarrabi
Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA
1 shared publicationAnaanya Nasta
Challenges in Managing and Preventing Pain (CHAMPP) Clinical Research Center Division of General Internal Medicine Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA
1 shared publication
Latest Publications
- 15 May 2026
- Published by Elsevier in Pain Management Nursing
- Vol. 27 (5) , e947-e956
Symptom Networks in Postsurgical Cancer Pain Across Recovery Stages
- 15 May 2026
- Published by Elsevier in Pain Management Nursing
- Vol. 27 (5) , e947-e956
Symptom Networks in Postsurgical Cancer Pain Across Recovery Stages
- 5 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501124
Characterizing Relationships Between Daily Pain, Opioid Use, and Mood in Patients With Advanced Cancer Using Ecological Momentary Assessments
PURPOSE: In advanced cancer, pain symptoms, opioid use, and cognitive-emotional processes fluctuate day to day and may mutually reinforce one another. We used 28-day ecological momentary assessments (EMAs) to quantify within-person associations between daily pain and (a) interference, (b) opioid use and perceived efficacy, and (c) mood, and to test whether variability in pain catastrophizing moderates these associations. METHODS: Patients with advanced cancer receiving outpatient oncology care at a comprehensive cancer center completed once-daily EMAs for 28 days (N = 26 analyzed). Measures included worst/average/least pain, pain interference, short-acting opioid tablets (count) and perceived opioid efficacy, negative and positive affect, and daily catastrophizing. Multilevel models estimated same-day within-person associations, controlling for study day and between-person mean pain. Individuals' standard deviation of daily catastrophizing changes (catastrophizing variability) was tested as a moderator. RESULTS: Across 477 daily assessments (median 21/28 per participant), higher-than-usual worst pain was consistently associated with worse pain interference, higher short-acting opioid use, lower perceived opioid efficacy, and higher negative affect (all P < .01); Average and least pain showed smaller or nonsignificant effects. Greater day-to-day variability in catastrophizing was associated with worse pain. Among individuals whose pain catastrophizing fluctuated more, there was a stronger relationship between pain severity and interference, affect, and perceived opioid efficacy (inverse; P ≤ .01). CONCLUSION: Greater day-to-day fluctuations in pain catastrophizing were associated with magnified correspondence of pain severity with interference, mood disruption, and perceived opioid inefficacy. Routine monitoring of pain severity combined with tracking catastrophizing variability may help identify high-risk days and inform in-the-moment support to better personalize pain management.
- 5 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501124
Characterizing Relationships Between Daily Pain, Opioid Use, and Mood in Patients With Advanced Cancer Using Ecological Momentary Assessments
PURPOSE: In advanced cancer, pain symptoms, opioid use, and cognitive-emotional processes fluctuate day to day and may mutually reinforce one another. We used 28-day ecological momentary assessments (EMAs) to quantify within-person associations between daily pain and (a) interference, (b) opioid use and perceived efficacy, and (c) mood, and to test whether variability in pain catastrophizing moderates these associations. METHODS: Patients with advanced cancer receiving outpatient oncology care at a comprehensive cancer center completed once-daily EMAs for 28 days (N = 26 analyzed). Measures included worst/average/least pain, pain interference, short-acting opioid tablets (count) and perceived opioid efficacy, negative and positive affect, and daily catastrophizing. Multilevel models estimated same-day within-person associations, controlling for study day and between-person mean pain. Individuals' standard deviation of daily catastrophizing changes (catastrophizing variability) was tested as a moderator. RESULTS: Across 477 daily assessments (median 21/28 per participant), higher-than-usual worst pain was consistently associated with worse pain interference, higher short-acting opioid use, lower perceived opioid efficacy, and higher negative affect (all P < .01); Average and least pain showed smaller or nonsignificant effects. Greater day-to-day variability in catastrophizing was associated with worse pain. Among individuals whose pain catastrophizing fluctuated more, there was a stronger relationship between pain severity and interference, affect, and perceived opioid efficacy (inverse; P ≤ .01). CONCLUSION: Greater day-to-day fluctuations in pain catastrophizing were associated with magnified correspondence of pain severity with interference, mood disruption, and perceived opioid inefficacy. Routine monitoring of pain severity combined with tracking catastrophizing variability may help identify high-risk days and inform in-the-moment support to better personalize pain management.
- Open Access
The 3P‐CP model: Expanding our conceptualization of cancer pain
Cancer pain is a complex, multifactorial, and growing public health challenge affecting millions of Americans. Effective pain management is essential for comprehensive cancer care, influencing physical and mental health, quality of life, and functional ability. However, progress in cancer pain management is hindered by the complexity of the issue and a fragmented understanding of the myriad factors shaping the pain experience. Additionally, traditional pain terminology—“acute” (<6 months) and “chronic” pain (≥6 months)—offers limited utility in cancer contexts, highlighting the need for a more nuanced framework. To address this gap, we propose the 3P‐CP model, which conceptualizes cancer pain through three interconnected phases: predisposing factors that increase cancer pain risk, precipitating factors that trigger cancer pain onset, and perpetuating factors that sustain or exacerbate cancer pain over time. This model provides a structured approach to assess the dynamic nature of cancer pain across the entirety of the cancer trajectory. In this paper, key factors associated with each phase of the 3P‐CP model are outlined and their implications for research and clinical care explored. Aligning with the oncology field's shift toward precision medicine, the 3P‐CP model has the potential to guide comprehensive assessment, risk mitigation, prevention, and intervention strategies—supporting efforts to deliver the right targeted and tailored treatments, to the right patients, at the right time.
Open AccessThe 3P‐CP model: Expanding our conceptualization of cancer pain
Cancer pain is a complex, multifactorial, and growing public health challenge affecting millions of Americans. Effective pain management is essential for comprehensive cancer care, influencing physical and mental health, quality of life, and functional ability. However, progress in cancer pain management is hindered by the complexity of the issue and a fragmented understanding of the myriad factors shaping the pain experience. Additionally, traditional pain terminology—“acute” (<6 months) and “chronic” pain (≥6 months)—offers limited utility in cancer contexts, highlighting the need for a more nuanced framework. To address this gap, we propose the 3P‐CP model, which conceptualizes cancer pain through three interconnected phases: predisposing factors that increase cancer pain risk, precipitating factors that trigger cancer pain onset, and perpetuating factors that sustain or exacerbate cancer pain over time. This model provides a structured approach to assess the dynamic nature of cancer pain across the entirety of the cancer trajectory. In this paper, key factors associated with each phase of the 3P‐CP model are outlined and their implications for research and clinical care explored. Aligning with the oncology field's shift toward precision medicine, the 3P‐CP model has the potential to guide comprehensive assessment, risk mitigation, prevention, and intervention strategies—supporting efforts to deliver the right targeted and tailored treatments, to the right patients, at the right time.
- 25 July 2025
- Published by Wolters Kluwer Health in Cancer Nursing
Factors Associated With the Delay of Chemotherapy Initiation Among Patients Receiving Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer
Background: Neoadjuvant and adjuvant breast cancer chemotherapy have been shown to improve survival outcomes, highlighting the importance of timely therapy. Objective: The study described the time to initiation of neoadjuvant or adjuvant chemotherapy among women with early-stage breast cancer and identified correlates of delay, including demographics, social determinants of health, patient factors, and symptom distress. Methods: The study utilized baseline data from the Symptom Experience and Management of cancer Outcomes According to Race and Social Demographics of Health, a multisite, longitudinal study that racially compared the time to chemotherapy initiation with consideration of social determinants of health. Logistic regression models analyzed the factors influencing chemotherapy initiation within the recommended timeframes (35 days for neoadjuvant therapy and 60 days for adjuvant therapy) after biopsy (neoadjuvant) or surgery (adjuvant). Results: Of the 256 patients included in the study, 56.5% (n = 145), received neoadjuvant therapy, and among them, 55.2% (n = 80) initiated chemotherapy within 35 days of biopsy. In the study, 43.4% (n = 111) received adjuvant therapy, with 77.5% (n = 86) initiating chemotherapy within 60 days. In univariate analysis, patients who began neoadjuvant therapy within 35 days had significantly higher Interpersonal Support Evaluation List appraisal scores. In multivariate regression analysis, symptom distress emerged as a significant predictor of the delay in initiation of adjuvant chemotherapy. Conclusion: Social support and symptom distress are considerations in chemotherapy initiation delay. Implications for Practice: Targeted interventions to alleviate symptom distress and enhance interpersonal support may facilitate timely chemotherapy initiation.
- 25 July 2025
- Published by Wolters Kluwer Health in Cancer Nursing
Factors Associated With the Delay of Chemotherapy Initiation Among Patients Receiving Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer
Background: Neoadjuvant and adjuvant breast cancer chemotherapy have been shown to improve survival outcomes, highlighting the importance of timely therapy. Objective: The study described the time to initiation of neoadjuvant or adjuvant chemotherapy among women with early-stage breast cancer and identified correlates of delay, including demographics, social determinants of health, patient factors, and symptom distress. Methods: The study utilized baseline data from the Symptom Experience and Management of cancer Outcomes According to Race and Social Demographics of Health, a multisite, longitudinal study that racially compared the time to chemotherapy initiation with consideration of social determinants of health. Logistic regression models analyzed the factors influencing chemotherapy initiation within the recommended timeframes (35 days for neoadjuvant therapy and 60 days for adjuvant therapy) after biopsy (neoadjuvant) or surgery (adjuvant). Results: Of the 256 patients included in the study, 56.5% (n = 145), received neoadjuvant therapy, and among them, 55.2% (n = 80) initiated chemotherapy within 35 days of biopsy. In the study, 43.4% (n = 111) received adjuvant therapy, with 77.5% (n = 86) initiating chemotherapy within 60 days. In univariate analysis, patients who began neoadjuvant therapy within 35 days had significantly higher Interpersonal Support Evaluation List appraisal scores. In multivariate regression analysis, symptom distress emerged as a significant predictor of the delay in initiation of adjuvant chemotherapy. Conclusion: Social support and symptom distress are considerations in chemotherapy initiation delay. Implications for Practice: Targeted interventions to alleviate symptom distress and enhance interpersonal support may facilitate timely chemotherapy initiation.
- 8 August 2023
- Published by Elsevier in Pain Management Nursing
- Vol. 25 (1) , 56-61
Dynamic Associations Between Daily Pain and Mood during Chemotherapy for Gynecologic Cancers
- 8 August 2023
- Published by Elsevier in Pain Management Nursing
- Vol. 25 (1) , 56-61
Dynamic Associations Between Daily Pain and Mood during Chemotherapy for Gynecologic Cancers